top of page
Abstract Line Pattern

Biliary Tract Cancer

< Back

Biliary Tract Cancer

(DESTINY-BTC01) A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig Versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer

Previous
Next

Principal Investigator (PI)

Clinical Trials.gov ID

Key Eligibility

Protocol #

SPONSOR

AstraZeneca
bottom of page